Daniel Freeman Selected Research

Paranoid Disorders (Paranoia)

7/2022	Bridging the Digital Divide in Psychological Therapies: Observational Study of Engagement With the SlowMo Mobile App for Paranoia in Psychosis.
1/2022	The service user experience of SlowMo therapy: A co-produced thematic analysis of service users' subjective experience.
1/2022	A compassionate imagery intervention for patients with persecutory delusions.
1/2022	SlowMo therapy, a new digital blended therapy for fear of harm from others: An account of therapy personalisation within a targeted intervention.
1/2021	Effects of SlowMo, a Blended Digital Therapy Targeting Reasoning, on Paranoia Among People With Psychosis: A Randomized Clinical Trial.
1/2018	The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group.
11/2017	SlowMo, a digital therapy targeting reasoning in paranoia, versus treatment as usual in the treatment of people who fear harm from others: study protocol for a randomised controlled trial.
10/2017	The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis.
11/2015	Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.
9/2015	Adult attention deficit hyperactivity symptoms and psychosis: Epidemiological evidence from a population survey in England.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Freeman Research Topics

Disease

27	Psychotic Disorders (Schizoaffective Disorder) 07/2022 - 08/2006
14	Paranoid Disorders (Paranoia) 07/2022 - 05/2005
10	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2021 - 07/2013
6	Neoplasms (Cancer) 12/2022 - 03/2010
6	Hallucinations (Hallucination) 10/2017 - 07/2013
5	COVID-19 12/2022 - 01/2021
4	Schizophrenia (Dementia Praecox) 01/2022 - 07/2014
3	Mental Disorders (Mental Disorder) 01/2018 - 06/2005
3	Sarcoma (Soft Tissue Sarcoma) 08/2013 - 06/2011
2	Infections 05/2022 - 10/2021
2	Weight Gain 01/2022 - 01/2020
2	Sleep Wake Disorders 01/2021 - 05/2018
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2021 - 12/2016
2	Wounds and Injuries (Trauma) 12/2016 - 07/2008
1	Hematologic Neoplasms (Hematological Malignancy) 12/2022
1	Thrombosis (Thrombus) 12/2022
1	Disease Progression 06/2022
1	Multiple Sclerosis 05/2022
1	Systemic Scleroderma (Systemic Sclerosis) 07/2021
1	Specific Phobia 06/2021
1	Phobic Disorders (Phobia) 06/2021
1	Sleepiness 01/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Acrophobia 01/2018
1	Hyperthyroidism 01/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 09/2015
1	Anhedonia 07/2014
1	Hemorrhage 09/2008
1	Fibrosis (Cirrhosis) 09/2008
1	Hemosiderosis 09/2008
1	Pulmonary Edema 09/2008
1	Hypertrophy 09/2008
1	Hyperuricemia 12/2005
1	Atherosclerosis 12/2005
1	Lactic Acidosis 12/2005
1	Cataract (Cataracts) 12/2005

Drug/Important Bio-Agent (IBA)

6	VaccinesIBA 12/2022 - 01/2021
6	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 07/2019
5	COVID-19 VaccinesIBA 12/2022 - 06/2021
3	Polytetrafluoroethylene (Teflon)FDA Link 07/2019 - 03/2015
3	Illicit Drugs (Recreational Drugs)IBA 09/2015 - 07/2008
3	Adenosine Triphosphate (ATP)IBA 08/2013 - 06/2011
3	src-Family KinasesIBA 08/2013 - 06/2011
2	Pharmaceutical PreparationsIBA 01/2021 - 03/2015
2	chemotactic factor inactivatorIBA 01/2021 - 04/2010
2	SolutionsIBA 11/2018 - 07/2014
2	Dihydrotachysterol (AT 10)IBA 10/2017 - 05/2015
2	Dronabinol (THC)FDA LinkGeneric 11/2015 - 03/2015
2	Protein Kinases (Protein Kinase)IBA 08/2013 - 08/2011
2	N 30IBA 06/2005 - 05/2005
1	IpilimumabIBA 01/2020
1	NivolumabIBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2019
1	CannabidiolIBA 01/2018
1	Formaldehyde (Formol)FDA Link 01/2017
1	Neuregulin-1 (Neuregulin 1)IBA 01/2017
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2017
1	patritumabIBA 01/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017
1	histidine-rich proteinsIBA 01/2017
1	ParaffinIBA 01/2017
1	A-factor (Streptomyces)IBA 07/2016
1	Amphetamine (Amfetamine)FDA LinkGeneric 09/2015
1	Cocaine (Cocaine HCl)IBA 09/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2013
1	GoldIBA 08/2013
1	tau-tubulin kinaseIBA 08/2013
1	Glycogen Synthase Kinase 3IBA 08/2013
1	Casein Kinase II (Casein Kinase 2)IBA 08/2011
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 08/2011
1	Ethylene Glycol (Monoethylene Glycol)IBA 08/2011
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 08/2011
1	Proteins (Proteins, Gene)FDA Link 06/2011
1	Peptides (Polypeptides)IBA 06/2011
1	isoleucyl-tyrosineIBA 06/2011
1	IronIBA 09/2008
1	Dopamine (Intropin)FDA LinkGeneric 07/2008
1	Biological ProductsIBA 10/2006
1	FructoseIBA 12/2005

Therapy/Procedure

31	Therapeutics 07/2022 - 08/2006
2	Aftercare (After-Treatment) 01/2022 - 12/2016
2	Secondary Prevention 06/2008 - 10/2007
1	Injections 06/2021
1	Immunotherapy 02/2019
1	Intravenous Administration 03/2015